Spain’s Medical-Cannabis System Appears to Reach Its First Product Registrations

Spain appears to have logged its first two cannabis preparations into the new registry

Spain’s medical-cannabis framework appears to have crossed an important line. Curaleaf said on 13 July that Spain’s medicines agency, AEMPS, formally registered two standardized cannabis preparations under Royal Decree 903/2025, with registry numbers CAN-1 and CAN-2.

The company said one preparation is THC-dominant and the other is CBD-dominant. If that statement is accurate, this is the first visible sign that Spain’s 2025 medical-cannabis decree is now working at the product level, not just on paper and not just in cultivation permits.

That matters because Spain did not build a broad consumer market. It built a narrow medical channel. The practical test was never whether the country could publish a decree. It was whether a manufacturer could get a cannabis preparation through the new registry and into the hospital-pharmacy compounding system that the decree created.

The distinction is important. These are not ordinary branded prescription medicines in the familiar European sense, with a full marketing authorization and a mass-market pharmacy rollout. They are standardized cannabis inputs that can be used within a regulated compounding pathway. In plain terms, the state is allowing registered cannabis ingredients to be turned into patient-specific preparations by hospital pharmacies under national rules.

AEMPS, the Spanish Agency of Medicines and Medical Devices, laid out that pathway in stages. Royal Decree 903/2025 created the public registry for standardized cannabis preparations and set the conditions for how those preparations could be used and dispensed. In January, AEMPS published the application procedure for registration. In February, it published the core information page for the regime. Those moves explained the system. The Curaleaf statement suggests the system has now started producing entries.

There is still an important boundary around the claim. The identity of the registrant and the CAN-1 and CAN-2 numbering come from Curaleaf’s company announcement, not from a separate AEMPS press release naming those products. The regulator’s legal and procedural documents show that the registry exists and that companies can apply. The company statement indicates that two products have now made it through.

For the industry, that is enough to change the conversation. Spain’s cannabis debate has often been dominated by rulemaking, parliamentary discussion and cultivation permissions. Product registration moves the story into a more practical phase: who can supply, who can manufacture to the required standard, and who can serve the hospital channel.

Royal Decree 903/2025 was built for hospital compounding, not a conventional drug launch

To understand why these two registrations matter, it helps to understand what Spain actually authorized.

Royal Decree 903/2025 did not create a general retail medical-cannabis market. It created a framework for “standardized cannabis preparations” to be used in “fórmulas magistrales tipificadas.” In everyday language, that means a registered cannabis preparation with fixed quality and cannabinoid content can be used by a pharmacy to make a prescribed preparation for an individual patient under a nationally defined formula.

The pharmacy at the center of this system is the hospital pharmacy, not the ordinary high-street chemist. That is one reason the framework has looked slower and more institutional than some patients or operators expected. Spain chose a controlled medical route, with a state-defined formula architecture, instead of a looser access model built around direct retail sales of flower or oils.

AEMPS’s National Formulary makes that architecture easier to see. The formulary entry FN/2026/FMT/043 sets out a standardized magistral formula for an oral solution using THC- and CBD-dominant standardized cannabis preparations. That means the regulator did not simply say cannabis may be used in theory. It established a specific compounded dosage form, in this case an oral solution, around registered source preparations.

That is why registry entry matters so much. Without registered preparations, the compounding formula is largely theoretical. With registered preparations, the hospital-pharmacy route becomes operational. A doctor can prescribe within the authorized framework, a hospital pharmacy can use a recognized input, and the system has a documented chain from manufacturer to patient.

The registration process itself also tells the market what Spain values. AEMPS’s January notice made clear that laboratories must apply for inclusion in the registry. In Spanish medicines regulation, “laboratory” means the pharmaceutical company or manufacturer responsible for the product, not a scientific lab bench. The applicant must present the quality, composition and control information that lets the regulator decide whether a preparation fits the standardized framework.

This is a narrower gate than a cultivation licence. A company may be allowed to grow cannabis under narcotics controls and still not be in a position to supply the new medical channel. To supply this channel, it needs a preparation that meets the product rules, a manufacturing setup that satisfies pharmaceutical quality expectations, and the administrative capacity to pass through AEMPS’s registration process.

That also helps explain why EU-GMP capability matters. EU-GMP is the European Union’s manufacturing quality standard for medicinal products. In practice, it is the operating language of regulated pharmaceutical supply. Spain’s framework may be cannabis-specific, but the system it plugs into is still medicine manufacturing and hospital dispensing. Companies that already understand validated production, batch consistency and controlled release are structurally better placed to compete.

The result is a framework that looks less like a consumer launch and more like a pharmaceutical input market. The registered product is the starting material for a controlled dispensing route, not the end point of a retail brand strategy.

The first registrations start separating paper licence holders from actual suppliers

That shift from legal possibility to registered supply is where the commercial significance sits.

For operators, Spain is no longer just a story about securing a permit or waiting for implementation. It is becoming a test of conversion. Can a company turn Spanish authorization, European manufacturing quality systems and a workable supply chain into a product that enters the registry and reaches the hospital-pharmacy pathway? The first registrations suggest that the answer is now yes for at least one operator.

That does not mean the market instantly becomes large. It means the hierarchy becomes clearer. The valuable position is not simply holding cannabis assets in Spain. The valuable position is being able to move through the regulator’s product gate and become a usable supplier in the medical system that Spain actually built.

This matters for cultivators as well. AEMPS’s active list of cannabis cultivation authorizations shows that Spain’s authorized production base remains relatively narrow. But cultivation on its own is not the decisive point anymore. A grower that cannot link its output to a registered preparation and a compliant manufacturing route is still outside the commercial center of gravity.

For hospital pharmacies, the change is practical. A hospital pharmacist does not need political consensus in the abstract. A hospital pharmacist needs a recognized preparation, a defined national formula and a lawful dispensing channel. The National Formulary already showed the formula side of that equation. Product registrations begin to supply the missing ingredient side.

For patients and prescribers, the effect is more measured than the headline may suggest. A registration does not by itself guarantee broad access, rapid uptake or national uniformity. Hospital systems need procedures. Prescribers need familiarity. Supply contracts and pharmacy routines need to be built. The public framework points to a lawful route, but it does not prove that the route will be equally active across Spain from the start.

For policy watchers, these registrations also sharpen the distinction between Spain and some other European medical-cannabis models. Spain has not chosen a large import-and-dispense flower market through ordinary pharmacies. It has chosen a more bounded pathway anchored in registered preparations and hospital compounding. That is a medical system with tight institutional control, not a liberalized commercial field.

For investors and corporate planners, the practical indicators also change. The key documents are no longer only decrees, consultation papers and cultivation rosters. The more revealing signals are now registry entries, formulary expansion, manufacturer participation and evidence that hospital dispensing is actually taking place. In other words, the operational record starts to matter more than the political promise.

Curaleaf’s announcement may therefore have value beyond the company itself. It indicates what the first real bottleneck looked like and who appears to have cleared it first. Even if other operators follow quickly, the first visible registrations show that Spain’s market is likely to reward pharmaceutical execution more than broad cannabis positioning.

Spain has moved beyond medical-cannabis symbolism, but the market stays narrow by design

The strongest conclusion from this moment is not that Spain has opened a major new cannabis market. It is that Spain has started to activate a deliberately narrow one.

That difference is easy to miss. For several years, Spain’s medical-cannabis debate produced headlines about reform while leaving the core commercial question unresolved. The unresolved question was whether the state would authorize a product architecture that someone could actually use. With two apparent registrations now on the record, that question begins to settle.

But the narrowness of the design should not be mistaken for a temporary inconvenience. It is the model. Hospital-pharmacy dispensing is not a transitional phase before ordinary retail access. The national formulary route is not a placeholder for a conventional branded market. The decree, the AEMPS procedure and the formulary all point in the same direction: Spain wants controlled medical use built around registered standardized inputs.

That has consequences for every part of the chain. Producers need to think like regulated suppliers, not commodity growers. Manufacturers need to think about consistency and dossier quality, not just extraction capacity. Commercial teams need to understand hospitals and pharmacy services, not just product launch tactics. The companies that misread Spain as a broad cannabis opening are likely to discover that the real gate sits inside the medicines system.

There are still material unknowns. Public information reviewed for this article does not answer every operational question that the market will care about, including the pace of additional registrations, how quickly hospitals adopt the pathway in practice, and how wide the effective prescribing base becomes. The regulator has published the framework. It has not yet published a large visible registry of active commercial movement around it.

That is why the CAN-1 and CAN-2 development matters despite its modest scale. Two registered preparations are not a market in themselves. They are proof that the market has started to exist in the form Spain chose.

The next phase will be less political and less theoretical. It will be about throughput. How many preparations enter the registry. How reliably they are supplied. How many hospital pharmacies actually compound and dispense them. Which operators can sustain pharmaceutical-grade execution rather than merely announce strategic intent.

Spain has now moved past the point where the industry could live on framework language alone. A decree can signal direction. A registry entry starts to define winners and losers.